ArticleJournal of medicinal chemistry2023
Structure-Based Discovery of Inhibitors of the SARS-CoV-2 Nsp14 N7-Methyltransferase.
Abstract read
In one paragraph
Article in Journal of medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Structural and Mechanistic Perspectives on SARS-CoV-2 Nonstructural Protein 14-Mediated Cap Formation and Drug Discovery.Microorganisms · 2026Review
- Prioritizing neuroactive ligands using motif-guided virtual discovery and zebrafish profiling.npj drug discovery · 2026Article
- Targeting SARS-CoV-2 Non-Structural Proteins: A Blueprint for Next-Generation Small-Molecule Coronavirus Antivirals.Pharmaceutics · 2026Review
- Fragment-Based Development of NSP14 Exonuclease Inhibitors Confounded by Batch-to-Batch Variability.ACS chemical biology · 2026Article
- Antiviral drug discovery and development: challenges and future directions.Signal transduction and targeted therapy · 2026Review
- Article
- Prioritizing Neuroactive Ligands Using Motif-Guided Virtual Discovery and Zebrafish Profiling.bioRxiv : the preprint server for biology · 2026Article
- Crystallographic characterisation and development of bi-substrate inhibitors of coronavirus nsp14 methyltransferase.RSC medicinal chemistry · 2026Article
- SARS-CoV-2 NSP14 inhibitor exhibits potent antiviral activity and reverses NSP14-driven host modulation.Nature communications · 2025Article
- Targeting SARS-CoV-2 main protease for the discovery of a broad-spectrum COVID-19 inhibitor by intensive multi-tiered validation.Acta pharmaceutica Sinica. B · 2025Article
- Cache: Utilizing ultra-large library screening in Rosetta to identify novel binders of the WD-repeat domain of Leucine-Rich Repeat Kinase 2.Journal of cheminformatics · 2025Article
- Discovery, Optimization, and Evaluation of Non-Nucleoside SARS-CoV-2 NSP14 Inhibitors.Journal of medicinal chemistry · 2025Article
- Discovery of Novel Isofunctional SARS-CoV‑2 NSP14 RNA Cap Methyltransferase Inhibitors by Structure-Based Virtual Screening.ACS medicinal chemistry letters · 2025Article
- Discovery of SARS-CoV-2 Nsp14-Methyltransferase (MTase) Inhibitors by Harnessing Scaffold-Centric Exploration of the Ultra Large Chemical Space.ACS pharmacology & translational science · 2025Article
- Mechanisms and rationales of SAM homeostasis.Trends in biochemical sciences · 2025Review
- Perspective for Drug Discovery Targeting SARS Coronavirus Methyltransferases: Function, Structure and Inhibition.Journal of medicinal chemistry · 2024Review
- Retrieval Augmented Docking Using Hierarchical Navigable Small Worlds.Journal of chemical information and modeling · 2024Article
- Structure-Based Virtual Screening for Methyltransferase Inhibitors of SARS-CoV-2 nsp14 and nsp16.Molecules (Basel, Switzerland) · 2024Article
- Article
- A Mini-Review on the Common Antiviral Drug Targets of Coronavirus.Microorganisms · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Isha SinghDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, California 94143, United States.
Fengling LiStructural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
Elissa A FinkDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, California 94143, United States.ORCID 0000-0001-5531-1971
Irene ChauStructural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
Alice LiDepartment of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario M5S 1A8, Canada.ORCID 0000-0003-1093-9698
Annía Rodriguez-HernándezDepartment of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, California 94158, United States.
Isabella GlennDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, California 94143, United States.
Francisco J Zapatero-BelinchónGladstone Institutes, San Francisco, California 94158, United States.ORCID 0000-0002-2751-8411
M Luis RodriguezDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
Kanchan DevkotaStructural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
Zhijie DengMount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences, Oncological Sciences and Neuroscience, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
Kris WhiteDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
Xiaobo WanDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, California 94143, United States.ORCID 0000-0003-4288-9074
Nataliya A TolmachovaEnamine Ltd, Kyïv 02094, Ukraine.
Yurii S MorozNational Taras Shevchenko University of Kyïv, Kyïv 01601, Ukraine.ORCID 0000-0001-6073-002X
H Ümit KaniskanMount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences, Oncological Sciences and Neuroscience, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.ORCID 0000-0001-5327-832X
Melanie OttGladstone Institutes, San Francisco, California 94158, United States.
Adolfo García-SastreDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
Jian JinMount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences, Oncological Sciences and Neuroscience, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.ORCID 0000-0002-2387-3862
Danica Galonić FujimoriDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, California 94143, United States.ORCID 0000-0002-4066-9417
John J IrwinDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, California 94143, United States.
Masoud VedadiStructural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.ORCID 0000-0002-0574-0169
Brian K ShoichetDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, California 94143, United States.ORCID 0000-0002-6098-7367
Funding
Targeting Viroporins and Coronavirus M ProteinU19AI171110 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Nevan J Krogan · 2022 to 2026
$103.4MSTRUCTURAL BIOLOGY TRAINING PROGRAMT32GM008284 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KORTEMME, TANJA · 1988 to 2022
$10.1MDevelopment and Testing of New Computational Methods for Ligand Discovery and MechanismR35GM122481 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Brian K Shoichet · 2017 to 2026
$8.5MA Web-Based Automatic Virtual Screening SystemR01GM071896 · NIGMS · UNIVERSITY OF TORONTO · PI IRWIN, JOHN J. · 2004 to 2024
$6.0MUltra-large library docking for ligand discoveryR01GM133836 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI IRWIN, JOHN J. · 2019 to 2022
$1.6MAn AVANCE NEO 400 MHz NMR Spectrometer for Chemical Biology and Drug DiscoveryS10OD028504 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI ZHOU, MING-MING · 2020 to 2020
$599kAn AVANCE NEO 600 MHz NMR Spectrometer System for Structural and Chemical BiologyS10OD025132 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI ZHOU, MING-MING · 2019 to 2019
$535kNIAID NIH HHS U19 AI171110NIGMS NIH HHS R01 GM071896NIGMS NIH HHS R01 GM133836NIGMS NIH HHS R35 GM122481NIGMS NIH HHS T32 GM008284NIH HHS S10 OD025132NIH HHS S10 OD028504
Abstract
An under-explored target for SARS-CoV-2 is the
Indexed as
COVID-19MethyltransferasesExoribonucleasesHumansRNA, ViralSARS-CoV-2Viral Nonstructural ProteinsExoribonucleasesMethyltransferasesRNA, ViralViral Nonstructural Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.